PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class ...

Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

Shares of PureTech Health plc (NASDAQ:PRTC – Get Free Report) were down 6.3% on Thursday . The stock traded as low as $17.04 and last traded at $17.55. Approximately 6,778 shares traded hands during ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food ...

(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia.

BOSTON, January 06, 2025 -- ( BUSINESS WIRE )-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), is pleased to announce that it has appointed UBS as its UK Corporate Broker ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed UBS as its UK Corporate Broker.